Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 12 2024 - 7:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the
Securities Exchange Act of 1934
February
12, 2024
Commission
File Number 001-14978
SMITH & NEPHEW plc
(Registrant’s
name)
Building 5, Croxley Park, Hatters Lane
Watford, England, WD18 8YE
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F Form 40-F
__
Smith+Nephew to attend AAOS 2024 Annual Meeting
12 February 2024
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
company, announces that it will be attending the American Academy
of Orthopaedic Surgeons (AAOS) 2024 Annual Meeting running from 12
to 16 February 2024 in San Francisco.
A number of commercial press releases are planned to coincide with
AAOS, including:
●
In
Orthopaedics Reconstruction, confirmation of our leading
robotic-assisted solutions for personalised orthopaedic surgery on
show.
●
In Trauma and Extremities, notification of the
commercial launch of the AETOS◊ Shoulder
System.
●
In Sports Medicine, the premiere of our expanded
biological healing portfolio, including the newly acquired
CARTIHEAL AGILI-C◊ Cartilage
Repair Implant alongside new applications for the
REGENETEN◊ Bioinductive
Implant.
In-line with prior years, Smith+Nephew will be hosting investors
and financial analysts attending the show, including booth tours
showcasing our products.
There will be no new information provided on current trading
performance or financial targets at AAOS. Smith+Nephew will publish
its Fourth Quarter and Full Year 2023 results on 27 February
2024.
Enquiries
Investors/ Analysts
Andrew Swift
+44
(0) 1923 477433
Katharine
Rycroft
+44 (0) 7811 270734
Smith+Nephew
Media
Charles Reynolds
+44 (0) 1923 477314
Smith+Nephew
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists
to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 19,000 employees deliver this mission every
day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new
technologies across our three global business units of
Orthopaedics, Advanced Wound Management and Sports Medicine &
ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in
2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,
NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer
to Smith & Nephew plc and its consolidated subsidiaries, unless
the context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and
follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading profit margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: economic
and financial conditions in the markets we serve, especially those
affecting healthcare providers, payers and customers; price levels
for established and innovative medical devices; developments in
medical technology; regulatory approvals, reimbursement decisions
or other government actions; product defects or recalls or other
problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims;
legal and financial compliance risks and related investigative,
remedial or enforcement actions; disruption to our supply chain or
operations or those of our suppliers; competition for qualified
personnel; strategic actions, including acquisitions and disposals,
our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; relationships with healthcare
professionals; reliance on information technology and
cybersecurity; disruptions due to natural disasters, weather and
climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation
regulations; effects of foreign exchange volatility; and numerous
other matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with
the U.S. Securities and Exchange Commission under
the U.S. Securities Exchange Act of 1934, as amended,
including Smith+Nephew's most recent annual report on Form 20-F,
which is available on the SEC's website at www. sec.gov, for a
discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
◊ Trademark
of Smith+Nephew. Certain marks registered in US Patent and
Trademark Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
Smith & Nephew plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
Date:
February 12, 2024
|
By:
|
/s/
Helen Barraclough
|
|
|
Helen
Barraclough
|
|
|
Company
Secretary
|
Smith and Nephew (PK) (USOTC:SNNUF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Smith and Nephew (PK) (USOTC:SNNUF)
Historical Stock Chart
From Aug 2023 to Aug 2024